Home › Liver Diseases › Pennsylvania
Liver Diseases clinical trials in Pennsylvania
8 studies for Liver Diseases are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Philadelphia
- 89bio Clinical Study Site, Pittsburgh
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374Primary Sclerosing Cholangitis in Children
- The Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
Ages 2 to 25 · All sexes · Updated Jul 14, 2026 · NCT04181138A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06600321DILIN - Prospective Study
- Thomas Jefferson, Philadelphia
RecruitingObservational studyHealthy volunteers welcome
Ages 2 and older · All sexes · Updated Apr 8, 2026 · NCT00345930A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
- Albert Einstein Healthcare Network, Philadelphia
Recruiting
Ages 18 and older · All sexes · Updated Oct 24, 2025 · NCT05733832Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
- Children's Hospital of Philadelphia, Philadelphia
- Children Hospital of Pittsburgh, Pittsburgh
RecruitingObservational study
All ages · All sexes · Updated May 25, 2025 · NCT06193928Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University, Dept of Radiology, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Feb 11, 2025 · NCT05470205From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.